A Closer Look at 14 Analyst Recommendations For Sarepta …

Jan 10, 2024 · A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics. Benzinga. Jan. 10, 2024, 11:00 AM ... Stay up to date on Sarepta Therapeutics analyst …

14%
OFF

What Analysts Are Saying About Sarepta Therapeutics Stock

2 weeks from now

May 2, 2024 · Observing a 8.14% increase, the current average has risen from the previous average price target of $145.38. ... Stay up to date on Sarepta Therapeutics analyst ratings.

businessinsider.com

$173.14
OFF

The Latest Analyst Ratings For Sarepta Therapeutics

2 weeks from now

Mar 3, 2023 · These 14 analysts have an average price target of $173.14 versus the current price of Sarepta Therapeutics at $156.37, implying upside. ... Stay up to date on Sarepta …

businessinsider.com

$158.87
OFF

A Glimpse Into The Expert Outlook On Sarepta Therapeutics

2 weeks from now

Dec 19, 2024 · Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $158.87, accompanied by a high estimate of $205.00 and …

nasdaq.com

$176.93
OFF

Unveiling 15 Analyst Insights On Sarepta Therapeutics - Nasdaq

2 weeks from now

Oct 21, 2024 · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $176.93, along with a high estimate of $205.00 and a low …

nasdaq.com

$66
OFF

Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

2 weeks from now

11 hours ago · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $66.5, with a high estimate of $111.00 and a low estimate of …

benzinga.com

FAQs about A Closer Look at 14 Analyst Recommendations For Sarepta … Coupon?

How do analysts evaluate Sarepta Therapeutics?

Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sarepta Therapeutics compared to the broader market. Price Targets: Understanding forecasts, analysts offer estimates for Sarepta Therapeutics's future value. ...

How can I view Sarepta Therapeutics's market performance?

To gain a panoramic view of Sarepta Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table. Stay up to date on Sarepta Therapeutics analyst ratings. ...

Why do analysts'maintain' or 'raise' their stance on Sarepta Therapeutics?

Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. ...

Why has Ritu Baral rated Sarepta Therapeutics a buy?

Ritu Baral has given her Buy rating due to a combination of factors that highlight the strong performance and future potential of Sarepta Therapeutics. The company’s preliminary revenue figures for Q4 and FY24 surpassed expectations, with Elevidys and PMO franchise revenues significantly beating both internal estimates and consensus. ...

How much will Sarepta Therapeutics cost?

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $128.79, a high estimate of $224.00, and a low estimate of $40.00. Observing a downward trend, the current average is 15.39% lower than the prior average price target of $152.22. ...

How does Sarepta Therapeutics compare to other health care companies?

As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector. Net Margin: Sarepta Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. ...